X-Vax Technology is developing a novel vaccine for both the prophylaxis and treatment of herpes simplex virus Type 1 and Type 2 in adults and children. The vaccine candidate was developed in a research laboratory at the Albert Einstein College of Medicine and has been used to characterize the immune response in animals which differs from that of former herpes simplex vaccine candidates. The vaccine confers “sterilizing immunity” with rapid viral clearance and protection from latency in a range of animal models following challenge with a wide range of virulent clinical isolates.


Back to Portfolio

Recent News